- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Hepatocellular carcinoma
- Meeting Date: July 2019
- Public Summary Document (PSD) July 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) July 2019 PBAC Meeting - (Word 181KB)
Cabozantinib – July 2019
Cabozantinib: Tablet 20 mg, Tablet 40 mg, Tablet 60 mg; Cabometyx®
Last updated
15 November 2019